Cargando…

Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis

BACKGROUND: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate. METHODS: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hua, Han, Han, He, Tianhui, Labbe, Kristen E, Hernandez, Adrian V, Chen, Haiquan, Velcheti, Vamsidhar, Stebbing, Justin, Wong, Kwok-Kin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665647/ https://www.ncbi.nlm.nih.gov/pubmed/33136163 http://dx.doi.org/10.1093/jnci/djaa168

Ejemplares similares

The current state of the art and future trends in RAS-targeted cancer therapies
por: Punekar, Salman R., et al.
Publicado: (2022)

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
por: Khunger, Monica, et al.
Publicado: (2017)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
por: Pan, Yuanwang, et al.
Publicado: (2022)

Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
por: Biswas, Sudipta, et al.
Publicado: (2023)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
por: Sehgal, Sameep, et al.
Publicado: (2016)

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
por: Velcheti, Vamsidhar, et al.
Publicado: (2013)

MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?
por: Pozza, Daniel Humberto, et al.
Publicado: (2020)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
por: Punekar, Salman R., et al.
Publicado: (2022)

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
por: Velcheti, Vamsidhar, et al.
Publicado: (2018)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
por: Huang, Min, et al.
Publicado: (2017)

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer
por: Huang, Qingyuan, et al.
Publicado: (2022)

Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images
por: Wang, Xiangxue, et al.
Publicado: (2017)

Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity
por: Hu, Hai, et al.
Publicado: (2021)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
por: Carvajal-Hausdorf, Daniel, et al.
Publicado: (2019)

Wellens’ syndrome: incidence, characteristics, and long-term clinical outcomes
por: Zhou, Li, et al.
Publicado: (2022)

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
por: Vaidya, Pranjal, et al.
Publicado: (2020)

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)

Approaches to multidrug-resistant organism prevention and control in long-term care facilities for older people: a systematic review and meta-analysis
por: Wong, Valerie Wing Yu, et al.
Publicado: (2022)

Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
por: Velcheti, Vamsidhar, et al.
Publicado: (2015)

A Novel Nodule Edge Sharpness Radiomic Biomarker Improves Performance of Lung-RADS for Distinguishing Adenocarcinomas from Granulomas on Non-Contrast CT Scans
por: Alilou, Mehdi, et al.
Publicado: (2021)

Comparison Between Automated Office Blood Pressure Measurements and Manual Office Blood Pressure Measurements—Implications in Individual Patients: a Systematic Review and Meta-analysis
por: Bo, Yacong, et al.
Publicado: (2021)

The many-faced KSR1: a tumor suppressor in breast cancer
por: Zhang, Hua, et al.
Publicado: (2015)

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
por: Tabassum, Neha, et al.
Publicado: (2020)

Uniportal versus multiportal video-assisted thoracoscopic anatomical resection for NSCLC: a meta-analysis
por: Yan, Yueren, et al.
Publicado: (2020)

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
por: McColl, Karen, et al.
Publicado: (2017)

A tumor vasculature–based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors
por: Alilou, Mehdi, et al.
Publicado: (2022)

Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer
por: Barrera, Cristian, et al.
Publicado: (2023)

Cystic glioblastoma: A systematic review and meta-analysis of characteristics and outcomes
por: Sae-Huang, Morrakot, et al.
Publicado: (2022)

Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
por: Ding, Ruiwen, et al.
Publicado: (2022)

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
por: Khunger, Monica, et al.
Publicado: (2018)

Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas
por: Alilou, Mehdi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_18vd84a9a6k4ng3encs5mutrmo